New York, Jan 26, 2026, 20:53 EST — Market closed.
- AbbVie shares ended Monday 0.7% higher, closing at $220.77.
- Wall Street closed up as investors braced for Wednesday’s Federal Reserve decision and a flood of mega-cap earnings reports.
- AbbVie will release its results before the market opens on Feb. 4, a crucial checkpoint for its growth prospects after Humira.
AbbVie Inc. shares ended Monday 0.7% higher, closing at $220.77, after fluctuating between $218.84 and $221.48 during the session.
The stock rise happened alongside a stronger Wall Street, with investors gearing up for the Federal Reserve’s policy announcement on Wednesday and earnings reports from major tech giants. “Communications and technology are outperforming … in anticipation of earnings from many of the big players,” said Chris Zaccarelli, chief investment officer at Northlight Asset Management. Reuters
AbbVie’s next key date is Feb. 4, when it will release its full-year and Q4 2025 results ahead of the market open. The company plans to host a webcast of its earnings call starting at 8 a.m. Central time.
Investors are closely monitoring if newer immunology treatments Skyrizi and Rinvoq can make up for Humira’s decline as U.S. biosimilars ramp up competition. Humira hit peak global sales exceeding $21 billion in 2022 before its U.S. patent expired.
Management is also betting on obesity as a fresh growth avenue. Chief medical officer Roopal Thakkar highlighted the company’s focus on “tolerability and durability of weight loss” for patients who stop using first-generation treatments, citing Gubra-licensed GUBamy, an amylin-mimicking drug. The market remains led by GLP-1 drugs — the gut-hormone class that includes Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Reuters
AbbVie has entered a licensing agreement with China’s RemeGen for RC148, a cancer drug candidate targeting PD-1 and VEGF, key proteins in tumor progression. The deal features a $650 million upfront payment, with up to $4.95 billion in milestone payments tied to development and sales goals, along with royalties on sales outside Greater China.
There have been setbacks as well. Genmab and AbbVie announced this month that a late-stage trial for their lymphoma drug, epcoritamab, did not achieve a statistically significant improvement in overall survival. They did highlight progress on other endpoints and said they plan to consult with regulators on the way forward.
Before Tuesday’s open, traders seem set to view AbbVie within the wider “quality” healthcare trade — known for steady cash flows and major product franchises — as the market holds for updates on rates and earnings.
Still, the stock remains vulnerable to familiar risks: sharper-than-anticipated Humira decline, setbacks in the pipeline, or intensifying pricing pressure out of Washington. A hawkish Fed surprise could shake dividend-heavy sectors too, especially if bond yields spike.
The market’s next big signal comes from the Fed’s policy statement on Wednesday afternoon. AbbVie investors, meanwhile, will be focused on Feb. 4, when the company reports results and guidance before the bell, offering updates on how fast new drugs are replacing Humira.
